(TPST) Tempest Therapeutics, Inc. ANSOFF Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TPST) Tempest Therapeutics, Inc. Complete Analysis Pack
Dive Deeper Into the Growth Paths Behind the Analysis
This Tempest Therapeutics, Inc. Ansoff Matrix Analysis maps growth options across market penetration, market development, product development, and diversification to show how the company can expand its oncology and immuno-oncology pipeline and enter new markets. The page contains a real preview/sample of the analysis so you can see style and substance before buying; purchase the full version to receive the complete ready-to-use report.
Market Penetration
TPST-1495 Phase 1 solid-tumor enrollment
Tempest Therapeutics can deepen penetration in oncology by advancing TPST-1495 in its first-in-human Phase 1 solid-tumor study, a direct way to build share of mind with trial sites already running cancer programs. More enrolled patients should expand the human data set on dual EP2/EP4 inhibition, the core biology behind this asset. A larger enrollment base also helps Tempest sharpen dose, safety, and early efficacy signals faster.
TPST-1120 Phase 1 solid-tumor enrollment
TPST-1120’s continued Phase 1 enrollment in solid tumors is a clear market penetration move, because Tempest Therapeutics, Inc. is keeping the same oncology program active in the same patient pool. The company has one lead small-molecule candidate in clinical testing, so steady enrollment helps preserve pipeline visibility while it stays clinical-stage. It also reinforces its niche in small-molecule oncology development.
Biomarker-guided patient selection
Biomarker-guided patient selection fits Tempest Therapeutics, Inc.’s market penetration play because its pathway-based drugs can be tested in the same solid-tumor market, but in patients most likely to respond. Solid tumors account for about 90% of adult cancers, so narrowing enrollment can improve response rates, speed readouts, and reduce wasted trial spend.
Combination-cohort expansion
Tempest Therapeutics can deepen market penetration by adding combination cohorts for TPST-1495 and TPST-1120 in solid tumors, where combo regimens are the trial norm. This lifts clinical relevance without changing the core oncology market, and it fits a capital-light expansion model for a company that reported about $15.2 million in cash and cash equivalents at year-end 2024.
- Broaden use in the same tumor classes
- Test more partners, same assets
- Raise trial relevance, not market scope
Conference and publication cadence
Tempest Therapeutics had no approved products in 2025, so steady Phase 1 readouts are a key market-penetration tool. In oncology, visibility at ASCO and ESMO can help drive investigator interest, site activation, and partner outreach; those meetings reach tens of thousands of specialists each year. For a small clinical-stage Company Name, cadence is commercial signal, not just science.
- More updates can support trial recruitment.
- Conference presence can lift partner attention.
- Regular data drops can widen competitive visibility.
Tempest Expands Solid-Tumor Testing With $15.2M Cash
Tempest Therapeutics, Inc. is using market penetration by deepening TPST-1495 and TPST-1120 testing in the same solid-tumor pool, with no approved products in 2025. Solid tumors make up about 90% of adult cancers, so each added cohort raises visibility without changing the market. The company had about $15.2 million in cash and cash equivalents at 2024 year-end.
| Metric | Value |
|---|---|
| Approved products | 0 in 2025 |
| Cash and cash equivalents | $15.2 million at 2024 year-end |
| Target market | Solid tumors, about 90% of adult cancers |
What is included in the product
Detailed Word Document
Provides a clear Ansoff Matrix framework for analyzing Tempest Therapeutics, Inc.’s growth strategy
Editable Excel File
Provides a clear Tempest Therapeutics Ansoff Matrix to quickly pinpoint growth options and reduce strategy-planning friction.
Reference Sources
Cites primary, regulatory, and peer-reviewed sources to validate Tempest Therapeutics’ Ansoff Matrix growth paths for fast, defensible decision-making.
Market Development
Additional solid-tumor indications
Tempest Therapeutics can expand its lead assets into additional solid-tumor settings, which fits its tumor-agnostic biology and avoids the cost of a new molecule. Solid tumors account for about 90% of adult cancers, so each new indication can lift the total addressable market fast. This kind of market development can extend one mechanism across multiple cancers, raising clinical optionality without a full R&D reset.
Broader oncology-center recruitment
Broader oncology-center recruitment is a market development move for Tempest Therapeutics, Inc. It keeps the same two lead assets, TPST-1495 and TPST-1120, but opens trial access to more patient pools and more clinicians. That wider site network can speed enrollment, with one program set and more centers.
New patient subgroups by pathway
Tempest can practice market development by using the same prostaglandin- and PPARalpha-driven assets to reach new, biomarker-defined patient groups. That widens the addressable population without changing the drug, which fits precision oncology. In 2025, Tempest still had just 2 core pathway themes to build on, so pathway-aligned recruitment can expand trial reach fast.
Geographic trial reach
Tempest Therapeutics, Inc. can widen trial reach by adding sites beyond South San Francisco, which helps recruit more patients and investigators without changing the drug. In oncology, faster enrollment matters because only about 3% to 5% of adults with cancer join clinical trials, so more geographies can reduce delay risk.
This is a low-change market development move: same assets, broader access, and better site diversity for readouts. It fits a clinical-stage company with no approved products and lets Tempest scale development before any commercial launch.
- Expand into new trial geographies
- Increase patient and investigator access
- Keep the investigational drugs unchanged
- Speed enrollment and de-risk timelines
Academic-oncology network expansion
Expanding into more academic oncology sites gives Tempest Therapeutics, Inc. access to new trial patients for the same assets, especially TPST-1495 and TPST-1120. NCI-designated cancer centers, which number 71 in the U.S., are key for biomarker testing and early efficacy reads in solid tumors, so this move can widen clinical reach without changing the drug program.
- More sites, same assets.
- Better biomarker and response data.
- Broader TPST-1495 and TPST-1120 exposure.
Tempest’s Growth Path: Bigger Solid-Tumor Markets, Faster Trial Reach
Tempest Therapeutics, Inc. can grow by moving TPST-1495 and TPST-1120 into more solid-tumor settings and more oncology sites. This market development keeps the same assets, but opens larger patient pools and faster enrollment. With only 2 core pathway themes in 2025, Tempest can scale reach without new chemistry.
| Move | Data |
|---|---|
| New indications | Solid tumors are about 90% of adult cancers |
| Trial access | Only 3% to 5% join cancer trials |
| Site reach | 71 U.S. NCI centers |
What You See Is What You Get
Tempest Therapeutics, Inc. Reference Sources
This is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report, so buy now to unlock the complete, editable Ansoff Matrix for Tempest Therapeutics with strategic recommendations and market actions.
Product Development
TREX-1 program advancement
TREX-1 program advancement is a clear product development move for Tempest Therapeutics, because it turns an explored biology into a defined drug asset. It would expand the oncology pipeline from 2 candidates, TPST-1495 and TPST-1120, to 3 programs, adding a new asset class rather than a new market. That widens Tempest Therapeutics, Inc.'s shot on goal without leaving oncology.
Next-generation EP2 and EP4 inhibitors
Tempest Therapeutics, Inc. can use TPST-1495 learnings to design next-generation EP2 and EP4 inhibitors with better potency, selectivity, and developability. That is product development because it upgrades the same receptor-inhibition franchise, not a new market. With no product revenue and continued R&D spending in the latest fiscal filings, a stronger successor around the same pathway could be the clearest way to add value.
Next-generation PPARalpha blockade
Tempest Therapeutics, Inc. can use TPST-1120 as the lead for a 2nd PPARalpha compound if more tuning is needed, keeping the program in the same target class while improving PK and safety.
That fits early oncology R&D, where back-up molecules are a standard step before expensive 2/3-stage trials; Phase 1/2 work often narrows risk fast.
With one lead asset already in hand, follow-ons can protect the platform and preserve value even if the first molecule needs optimization.
Translational biomarker package
Tempest Therapeutics, Inc. can pair pathway-driven small molecules with a translational biomarker package to raise product value by matching the right patients to the right drug and tracking early response signals in Phase 1 solid-tumor studies. This matters because proof-of-mechanism in Phase 1 often comes from small cohorts and can shape go/no-go calls fast.
- Improves patient selection
- Tracks early response
- Supports Phase 1 proof-of-mechanism
- Adds value to each program
Combination regimen refinement
Refining TPST-1495 and TPST-1120 combinations is product development, because Tempest Therapeutics, Inc. is changing how these assets are used in trials, not adding a new drug. In oncology, combo regimens often beat monotherapy, and Tempest’s Phase 2 work has centered on shaping a clinical profile that can support later-line use.
That matters because Tempest reported a $0 market cap with a small cash base and no approved products, so better regimen design can lift asset value faster than a single-agent path.
- Combo-first positioning can improve efficacy signals.
- Trial design shapes TPST-1495 and TPST-1120 value.
- Better regimens can support future partnering.
Tempest’s Value Case: Better Follow-Ons, Broader Pipeline
Tempest Therapeutics, Inc. uses product development to extend TPST-1495 and TPST-1120 into better-fit follow-ons, not new markets. Its latest filings still show no product revenue and a small cash base, so upgrading potency, selectivity, PK, and biomarker fit is the fastest path to value. A 3rd oncology asset widens the pipeline and keeps risk inside one franchise.
| Data point | Latest |
|---|---|
| Product revenue | 0 |
| Core oncology programs | 2 |
| Value lever | Follow-on assets |
Diversification
Multi-program pipeline beyond 2 clinical assets
Tempest Therapeutics, Inc. still has 2 named clinical candidates, so adding a 3rd program would widen its oncology pipeline and cut reliance on one mechanism or asset. That matters in a capital-light model, where each new program can spread clinical risk across more shots on goal. It also shifts the company from a narrow 2-asset story toward a broader oncology portfolio.
Innate-immunity mechanism expansion
Tempest Therapeutics, Inc.’s interest in TREX1 signals diversification into innate-immune regulation inside oncology, not a move into a new industry. That is a different path from EP2 and EP4 inhibition or PPARalpha blockade, so it broadens the future pipeline. It can widen the product set while still staying cancer-focused.
New small-molecule target classes
Tempest Therapeutics, Inc. reported no product revenue in FY2025, so adding new small-molecule target classes would broaden its science base beyond the two current mechanisms. That is a realistic discovery-led biotech move: one validated target can seed more than one future program. It also lowers pipeline concentration risk and can support longer-term value creation.
Additional solid-tumor biology programs
Tempest Therapeutics, Inc. can diversify by adding more distinct solid-tumor biology programs, so its pipeline is not tied to one pathway or one asset. That keeps the cancer focus intact while widening the shot at clinical success and reducing concentration risk, which matters most for a clinical-stage biotech with limited revenue and high R&D burn.
- More tumor pathways, broader portfolio
- Same oncology focus, less asset risk
- Better odds of pipeline survival
Future immuno-oncology assets
Tempest Therapeutics, Inc. can use its tumor-biology and immune-signaling know-how to add more immuno-oncology assets, which is a new product line in a new oncology niche. This is the clearest diversification path in its Ansoff Matrix because it extends the same research base into adjacent therapies.
The global oncology drug market was about $220 billion in 2024, so even one added immuno-oncology program can target a large addressable pool. The main risk is still high R&D burn, but the upside is a broader pipeline and less dependence on a single mechanism.
- New products, new niche
- Uses existing biology expertise
- Best-fit diversification route
Tempest’s 3rd Oncology Asset Could Cut Risk and Broaden Its Pipeline
Tempest Therapeutics, Inc. uses diversification to add more oncology programs without leaving cancer. With FY2025 product revenue of $0 and only 2 named clinical candidates, a 3rd asset would spread clinical risk, widen its mechanism mix, and reduce dependence on any one program.
| 2025/2026 view | Value |
|---|---|
| Product revenue FY2025 | $0 |
| Named clinical candidates | 2 |
| Diversification effect | Lower asset risk |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.